Zymeworks Inc. (ZYME)

↓ Download CSV

CIK 0001937653 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Zymeworks Inc. reported revenue of $105.97M, up 38.9% from the prior year. The company ran a net loss, with a net margin of -76.6%. It held $346.53M in total assets against $78.03M in total liabilities.

Key ratios (FY2025)

-87.3%
Operating margin
-76.6%
Net margin
-30.2%
Return on equity
+38.9%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$105.97M$76.30M$76.01M$412.48M$26.68M$38.95M
Operating Income-$92.55M-$137.11M-$138.05M$130.53M-$215.63M-$187.47M
Net Income-$81.13M-$122.69M-$118.67M$124.34M-$211.84M-$180.55M
EPS (Diluted)$-1.08$-1.62$-1.72$1.90$-4.61$-3.58
Total Assets$346.53M$463.09M$580.88M$648.73M$389.13M
Total Liabilities$78.03M$124.32M$116.07M$155.77M$140.04M
Shareholders' Equity$268.50M$338.77M$464.81M$492.96M$249.09M$409.92M$245.68M
Cash & Equivalents$41.16M$66.10M$157.56M$400.91M$201.87M
Operating Cash Flow-$33.01M-$110.06M-$118.32M$144.11M-$192.45M-$151.40M
Capital Expenditures$1.52M$1.99M$2.47M$8.15M$12.40M$4.31M
Shares Outstanding75.41M75.88M68.86M65.25M52.13M50.38M